A team of researchers has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1), a ...

The study, published in Lancet Neurology, detailed the "head-to-head" trial implemented by the researchers to test two drugs, ...

A team of researchers led by Instituto de Investigación Sanitaria de INCLIVA-Universitat de València, in collaboration with various other research sites, including Germans Trias i Pujol Research ...

Health and Social Research Center, Universidad de Castilla-La Mancha, Cuenca, Spain Facultad de Enfermería de Albacete, Universidad de Castilla-La Mancha, Albacete, Spain ...

Celnova will commercialize NaMuscla in Argentina and Colombia, for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders. NaMuscla is the first and only licensed ...

A team of researchers has identified a promising therapy based on antimiRs to treat myotonic dystrophy type 1 (DM1), a complex genetic disorder caused by an abnormally high number of CTG repeats ...

Non-dystrophic myotonias are life-changing muscle disorders caused by problems with ... showed it was effective in treating non-dystrophic myotonia and improving quality of life.

The distribution pact is for a drug indicated for the treatment of non-dystrophic myotonic disorders. Lupin Atlantis Holdings SA has inked the pact with Celnova. As per the pact, Celnova will ...

a drug commonly used to treat epilepsy and certain mood disorders, has been shown to be an excellent treatment option for a rare genetic neuromuscular disease known as non-dystrophic myotonia, in ...